Karfeld-Sulzer Lindsay S, Siegenthaler Barbara, Ghayor Chafik, Weber Franz E
Oral Biotechnology & Bioengineering, University Hospital, Division of Cranio-Maxillofacial and Oral Surgery and Center for Dental Medicine, University of Zurich, Plattenstrasse 11, Zurich CH-8032, Switzerland.
Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich CH-8006, Switzerland.
Materials (Basel). 2015 Mar 6;8(3):977-991. doi: 10.3390/ma8030977.
Current clinically used delivery methods for bone morphogenetic proteins (BMPs) are collagen based and require large concentrations that can lead to dangerous side effects. Fibrin hydrogels can serve as osteoinductive bone substitute materials in non-load bearing bone defects in combination with BMPs. Two strategies to even further optimize such a fibrin based system include employing more potent BMP heterodimers and engineering growth factors that can be covalently tethered to and slowly released from a fibrin matrix. Here we present an engineered BMP-2/BMP-7 heterodimer where an N-terminal transglutaminase substrate domain in the BMP-2 portion provides covalent attachment to fibrin together with a central plasmin substrate domain, a cleavage site for local release of the attached BMP-2/BMP-7 heterodimer under the influence of cell-activated plasmin. and results revealed that the engineered BMP-2/BMP-7 heterodimer induces significantly more alkaline phosphatase activity in pluripotent cells and bone formation in a rat calvarial model than the engineered BMP-2 homodimer. Therefore, the engineered BMP-2/BMP-7 heterodimer could be used to reduce the amount of BMP needed for clinical effect.
目前临床上用于递送骨形态发生蛋白(BMP)的方法是以胶原蛋白为基础的,需要高浓度使用,这可能会导致危险的副作用。纤维蛋白水凝胶可与BMP联合用作非承重骨缺损中的骨诱导性骨替代材料。进一步优化这种基于纤维蛋白的系统的两种策略包括使用更有效的BMP异二聚体以及构建可以共价连接到纤维蛋白基质并从其缓慢释放的生长因子。在此,我们展示了一种工程化的BMP-2/BMP-7异二聚体,其中BMP-2部分的N端转谷氨酰胺酶底物结构域与中央纤溶酶底物结构域一起提供与纤维蛋白的共价连接,该中央纤溶酶底物结构域是在细胞激活的纤溶酶影响下附着的BMP-2/BMP-7异二聚体局部释放的切割位点。结果显示,与工程化的BMP-2同二聚体相比,工程化的BMP-2/BMP-7异二聚体在多能细胞中诱导出显著更多的碱性磷酸酶活性,并在大鼠颅骨模型中诱导更多的骨形成。因此,工程化的BMP-2/BMP-7异二聚体可用于减少产生临床效果所需的BMP用量。